Johnson & Johnson today announced its pharmaceutical business segment will adopt the Johnson & Johnson brand name in Ireland. Janssen, its pharmaceutical segment, will become Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson MedTech.
The announcement marks the next era for Johnson & Johnson in Ireland, which is leveraging its expertise in innovative medicine and medical technology to prevent and treat complex diseases and introduce solutions that are smarter, less invasive, and more personalised.
Johnson & Johnson has a long heritage in Ireland since 1935, and a large footprint with a workforce of more than 6,000 people.1 Its Irish operations which comprise both the Innovative Medicine and MedTech segments, make a significant contribution to the company’s global success with ten sites located in five counties (Cork, Dublin, Limerick, Galway and Mayo) spanning research and development, manufacturing, shared services and country commercial businesses.
These changes are part of a global rollout of the new Johnson & Johnson brand that was announced in September 2023. The updated brand will be applied to all company materials, product packaging, and branding assets over time.
The new Johnson & Johnson brand identity builds on the Company’s legacy, while also modernising key elements to showcase healthcare innovation in a way that is inclusive and demonstrates the Company’s ability to tackle the world’s toughest health challenges.
Mr. Dana Daneshvari, VP Manufacturing & General Manager, Large Molecule Manufacturing, Johnson & Johnson Innovative Medicine, Ringaskiddy, said; “While the name and logo of the pharmaceutical segment of our business is changing, our goal remains the same. We innovate with purpose to lead where medicine is going. As we look to the future, we will continue to build on our legacy of innovation, delivering transformational medicines that improve patient outcomes and make a lasting impact on healthcare in Ireland.”
Johnson & Johnson Innovative Medicine applies rigorous science with compassion to confidently address the most complex diseases in the areas of oncology, immunology, neuroscience, cardiopulmonary and specialty ophthalmology to develop the potential medicines of tomorrow.
There will be no change to the company names and/or legal status of our Johnson & Johnson Innovative Medicine or MedTech companies in Ireland. The Johnson & Johnson Innovative Medicine companies are Janssen Sciences Ireland UC and Janssen Pharmaceutical Sciences UC.
For further information please contact:
Fiona Peppard – T: +353 87 635 4423, E: [email protected]
Sinead O’Donnell – T: +353 85 131 7677, E: sinead.o’[email protected]
ABOUT JOHNSON & JOHNSON
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Learn more at https://innovativemedicine.jnj.com/ireland/.
You can also follow us on LinkedIn here
The site you’re being redirected to is an external website where this Privacy Policy does not apply. Please click below to continue to that site.You are now leaving J&J Innovative Medicine Ireland
CP-488341 | November 2024